ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; p. viii466
Main Authors Ascierto, P.A., Arenberger, P., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H.M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S., Diab, A.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy289.062